Vontobel Holding Ltd. Has $32.66 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Vontobel Holding Ltd. increased its holdings in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 1.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 165,475 shares of the company’s stock after purchasing an additional 2,027 shares during the period. Vontobel Holding Ltd.’s holdings in Zoetis were worth $32,660,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Norges Bank acquired a new position in Zoetis in the 4th quarter valued at approximately $745,861,000. Morgan Stanley raised its holdings in Zoetis by 34.6% in the 4th quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock valued at $1,593,395,000 after acquiring an additional 2,796,694 shares in the last quarter. Moneta Group Investment Advisors LLC grew its stake in shares of Zoetis by 124,281.9% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 2,332,160 shares of the company’s stock valued at $341,778,000 after purchasing an additional 2,330,285 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in shares of Zoetis by 171.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,326,448 shares of the company’s stock valued at $627,335,000 after purchasing an additional 2,102,306 shares during the period. Finally, Vaughan Nelson Investment Management L.P. bought a new stake in shares of Zoetis in the 3rd quarter valued at approximately $176,219,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS stock opened at $151.00 on Monday. The company has a market cap of $69.06 billion, a P/E ratio of 29.58, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85. Zoetis Inc. has a twelve month low of $148.48 and a twelve month high of $201.92. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The business’s fifty day moving average is $179.92 and its 200-day moving average is $180.91.

Zoetis (NYSE:ZTSGet Free Report) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same period in the previous year, the business posted $1.15 EPS. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. Equities research analysts forecast that Zoetis Inc. will post 5.8 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 1.14%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio is 34.12%.

Analyst Upgrades and Downgrades

ZTS has been the topic of several analyst reports. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group increased their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Piper Sandler increased their price target on Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 20th. Barclays increased their price target on Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $230.00 price objective on shares of Zoetis in a research report on Tuesday, December 19th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $224.88.

Get Our Latest Analysis on ZTS

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the completion of the transaction, the executive vice president now owns 20,417 shares in the company, valued at approximately $4,037,257.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 2,209 shares of company stock valued at $408,453 in the last 90 days. 0.15% of the stock is currently owned by company insiders.

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read More

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.